OBJECTIVES:  This study aimed to estimate the patterns and cost burden among CF patients by focusing on annual and lifetime direct and indirect costs. METHODS:  Data were collected by using a study with a cross sectional design in 30 patients who visited the CF clinic of the Sultan Qaboos University Hospital (SQUH) in Oman between December 2014 and February 2015. Direct health-care costs reflecting the governmental perspective were determined retrospectively by Hospital Information System (HIS) whilst indirect costs reflecting the social perspective were collected prospectively by means of a questionnaire. Most sources for unit's costs were acquired from SQUH’s administrative price list of 2014. Prices of admissions, emergency, specialist and general practitioner (GP) visits were acquired from Muscat Private Hospital to reflect the actual market costs. RESULTS:  The total annual cost per patient averaged at €27,128 ± 42631 (year 2014 values). The majority of costs were spent on direct health costs with 91.8% (mean €25,508 ± 43014) while indirect costs were only 8% (mean €2,275 ± 56523). Pharmaceuticals represented 73.5% of the total costs with mean costs of €20,429 ± 41018. Of the total costs, 7% resulted from admissions and 2.9% were from laboratory tests. Lifetime costs were averaged nearly at €543,300 ± 763,832 (3% discount rate). CONCLUSIONS:  CF is associated with high annual direct and indirect cost in Oman. Pharmaceuticals, productivity losses and admissions accounted for the majority of total cost. The calculated lifetime costs were 20 fold higher than total annual costs.